X4 PHARMACEUTICALS, INC Proceeds from Sale of Intangible Assets
X4 PHARMACEUTICALS, INC (XFOR) reported Proceeds from Sale of Intangible Assets of $105.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2025-03-26
- X4 PHARMACEUTICALS, INC proceeds from sale of intangible assets for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC proceeds from sale of intangible assets for the quarter ending 2019-12-31 was $104.00K.
- X4 PHARMACEUTICALS, INC proceeds from sale of intangible assets for the quarter ending 2019-09-30 was $900.00K.
- X4 PHARMACEUTICALS, INC proceeds from sale of intangible assets for fiscal 2024 was $105.00M.
- X4 PHARMACEUTICALS, INC proceeds from sale of intangible assets for fiscal 2023 was $0.00.
- X4 PHARMACEUTICALS, INC proceeds from sale of intangible assets for fiscal 2022 was $0.00.
- X4 PHARMACEUTICALS, INC proceeds from sale of intangible assets for fiscal 2021 was $0.00.
| Period end | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 6 month | Proceeds from Sale of Intangible Assets 9 month | Proceeds from Sale of Intangible Assets 12 month |
|---|---|---|---|---|
| 2024-12-31 | $105.00M 10-K · filed 2025-03-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-17 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.00M derived: sum of 2 quarters · filed 2022-03-17 | $1.00M 10-K · filed 2022-03-17 | |
| 2019-09-30 | $900.00K 10-Q · filed 2019-11-07 | $896.00K 10-Q · filed 2020-11-05 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-03-19 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |